Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29684634 | 1.00 | CYP1A2 (0.66) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL2545268 | 0.94 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL10584222 | 0.94 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL16758741 | 0.94 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL20170926 | 0.90 | CYP1A2 (0.69) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL3066845 | 0.90 | CYP1A2 (0.69) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL29708563 | 0.89 | CYP1A2 (0.72) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL864648 | 0.89 | CYP1A2 (0.72) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| Potassium SCHEMBL30586884 | 0.87 | CYP1A2 (0.69) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 | |
| SCHEMBL8869388 | 0.85 | ALDH1A1 (0.53) | CYP1A2CYP2C9CYP2C19ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12263159-B2 | Fused ring compound having urea structure | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240285597-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2024-08-29 | — | — | US | disclosed |
| US-11918568-B2 | Fused ring compound having urea structure | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-03-05 | — | — | US | disclosed |
| EP-3906233-B1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-31 | — | — | EP | disclosed |
| US-20230152226-A1 | OPTICAL SENSORS | LUMIRADX UK LTD (GB) | 2023-05-18 | — | — | US | disclosed |
| EP-3818053-B1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-4121744-A1 | OPTICAL SENSORS FOR DETECTING THE PRESENCE OR AMOUNT OF A TARGET PRESENT IN A SAMPLE | LUMIRADX UK LTD (GB) | 2023-01-25 | — | — | EP | disclosed |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-11289238-B2 | Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2021-11-25 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| EP-0726254-B1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS (JP) | 1998-05-06 | — | — | EP | disclosed |
| EP-0726254-A1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-08-14 | — | — | EP | disclosed |
| US-4987258-A | Intermediates for disazo dyes | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-01-22 | — | — | US | disclosed |
| EP-0196574-B1 | 4,4'-DIAMINODIPHENYL COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-10-10 | — | — | EP | disclosed |
| EP-0303360-A1 | Electroconductive polymers | COOKSON GROUP plc (GB) | 1989-02-15 | — | — | EP | disclosed |
| EP-0242850-A1 | Water soluble monoazo compounds, process for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-10-28 | — | — | EP | disclosed |
| EP-0196574-A2 | 4,4'-Diaminodiphenyl compounds, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-10-08 | — | — | EP | disclosed |
| EP-0063275-A1 | Mono-azo dyestuff, its preparation and use | CASSELLA Aktiengesellschaft (DE) | 1982-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12263159-B2 | Fused ring compound having urea structure | NAMPT, NME4, NDUFAB1 | CYP1A2 3585/4885CYP2C9 3301/4885CYP2C19 2959/4885 |
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | NAMPT, NME4, ABAT | CYP1A2 3649/4885CYP2C9 3475/4885CYP2C19 3099/4885 |
| US-11918568-B2 | Fused ring compound having urea structure | NAMPT, NME4, ABAT | CYP1A2 3649/4885CYP2C9 3475/4885CYP2C19 3099/4885 |
| US-20240285597-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | NAMPT, NME4, NDUFAB1 | CYP1A2 3585/4885CYP2C9 3301/4885CYP2C19 2959/4885 |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | MAP3K20, MAP3K1, PACSIN2 | CYP1A2 4718/4885CYP2C9 4564/4885CYP2C19 4430/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | CYP1A2 982/4885CYP2C9 1824/4885CYP2C19 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.